This trial is not actively recruiting.

This trial has completed recruitment on this platform, and is no longer accepting new referrals.

A clinical trial of investigational flu, RSV, and COVID-19 vaccines for adults 50–75 years of age

Trial ID: mRNA-1230-P101
The Trio P101 Trial is a Phase 1 clinical trial conducted by Moderna to determine whether investigational vaccines can help protect adults 50 to 75 years of age from influenza (flu), respiratory syncytial virus (RSV), and COVID-19. The combination vaccines being studied in this clinical trial take 2 or more investigational vaccines that could potentially be given individually and put them into 1 injection. It is hoped that the investigational combination vaccines can potentially reduce the number of injections you need for protection against common viruses like flu, RSV, and COVID-19.

Trial Details

The purpose of the Trio P101 Trial is to assess the safety of and immune responses to investigational vaccines aimed at preventing illness due to 3 common viruses: flu, RSV, and COVID-19 in adults 50 to 75 years of age. Flu, RSV, and COVID-19 are all respiratory illnesses. Flu is caused by the influenza virus. COVID-19 is caused by the SARS-CoV-2 virus. You may be less familiar with RSV, which is one of the most common causes of lower respiratory tract infections worldwide. In this trial, 5 different investigational vaccines will be evaluated. All participants will be randomly assigned to one of the groups in the trial, which will determine which investigational vaccine and dose each participant receives. Each participant will only receive 1 investigational vaccine. In this clinical trial, the investigational vaccines are:

  • mRNA-1010: An investigational vaccine for the prevention of flu
  • mRNA-1045: An investigational combination vaccine for the prevention of flu and RSV
  • mRNA-1273.214: An investigational booster vaccine for the prevention of COVID-19 and some of its variants
  • mRNA-1345: An investigational vaccine for the prevention of RSV
  • mRNA-1230: An investigational combination vaccine for the prevention of flu, RSV, and COVID-19

Estimated Enrollment

675 Participants


Phase 1

Eligibility Criteria

Participants must:

  • Be 50 to 75 years of age
  • Be in good health
  • Be fully vaccinated for COVID-19 (with or without a booster) for at least 4 months

Participants must not:

  • Have a pre-existing medical condition that is not stable
  • Have participated in another clinical trial within the past month

Site Locations

Sites are located in the cities/states identified with the red pin:

What to Expect

Participation in the Trio P101 Trial will last approximately 13 months and includes 7 visits to a trial site and up to 8 safety phone calls. Participants will be given 1 injection of an investigational vaccine in the upper arm.

Participants will use an electronic diary (eDiary) through an app on their smartphone or a provided device, to record how they are feeling for 7 days after they receive the investigational vaccine. Participants will have follow-up visits at their clinical trial site over the course of the trial for tests that will show if the investigational vaccine is working.

Insurance is not needed to participate, and qualified participants will receive payment for their trial-related time and travel.

Frequently Asked Questions (FAQs)